Georgia's SB 444 bars insurers from denying coverage based solely on AI, requiring human review of every algorithmic denial starting January 2027, joining a wave of state laws regulating AI in claims review.
UpDoc's FDA-cleared insulin-management chatbot marks the first patient-facing LLM authorized as a medical device, with early deployments at Cleveland Clinic, UCSF Health, and Allegheny Health Network.
Northwestern University engineers printed flexible artificial neurons from graphene and molybdenum disulfide that successfully triggered responses in living mouse brain tissue, an early step toward energy-efficient neuromorphic computing and future brain-machine interfaces.
A study of 341 women presented at the Society of Breast Imaging Symposium found AI software detected signs of breast cancer on mammograms up to three years before radiologists diagnosed it, adding to evidence for AI-assisted screening even as billing and false-positive concerns persist.
Oura launched a proprietary AI model built specifically for women's health, then expanded it in May 2026 with new hormonal birth control and menopause insight features, part of a broader wave of femtech companies building AI tools for a historically underserved area of medicine.
Deep Origin says its AI platform, which blends physics-based simulation with machine learning, found viable cancer immunotherapy drug candidates at a 31% hit rate, nearly 100 times the industry's typical rate, though no AI-designed drug has yet won regulatory approval.
CVS Health won a 2026 Newsweek AI Impact Award for an AI tool that uses large language models to interpret complex prescription directions and calculate dosages across its nearly 9,000 retail pharmacies, part of a broader industry push to automate medication safety checks.
The Seattle Fire Department has used Danish AI company Corti to analyze every 911 medical call since December 2023, routing some callers to a nurse line instead of an ambulance, without disclosing the practice to the public or the city council.
Genetic testing giant Natera has launched a proprietary AI foundation model platform built on more than 250,000 tumor exomes and over a million plasma timepoints, aiming to predict which cancer patients will respond to immunotherapy before treatment starts.
Nurses with National Nurses United staged coordinated protests in eight U.S. cities demanding hospitals cut ties with Palantir's AI data platforms, days after NYC Health and Hospitals said it would not renew its own Palantir contract.